The global metalworking fluids market size is expected to reach USD 17.45 billion by 2030, as per the new report by Grand View Research, Inc., registering a CAGR of 4.9% in the forecast period. The demand is attributed to arise in demand for automotive and industrial machinery. Individual end-use sectors, such as machinery, metal fabrication, and transportation equipment, are driving the expansion of the market.
The market is also expected to be driven by strong development in the machinery and transportation equipment end-use industries over the projected period. Manufacturing is one of the core industries in North America and Europe. Advances in the manufacturing methods for the production of sophisticated end-use products, coupled with the increase in the exports of construction machinery and power, agricultural, and automotive equipment, have fueled the market growth.
The sector is expected to benefit from increased production of construction machines and related parts for industrial, residential, and commercial construction. The rise in public-private partnerships is expected to boost the demand for a variety of construction components that use MWFs during their production. Because of the expanding building activities in these nations, emerging economies are likely to be critical for product growth.
Gather more insights about the market drivers, restrains and growth of the Metalworking Fluids Market
Detailed Segmentation:
Market Concentration & Characteristics
The industry growth stage is moderate, and the pace of the growth is accelerating. The clinical trials market is characterized by a moderate-to-high degree of growth owing to increasing investment in R&D programs, growing preference for outsourcing activities to minimize time, curtail clinical trial cost and patent expiration of blockbuster drugs. With increasing clinical trial privatization, there is a surge in outsourcing to developing countries, and many CROs are enhancing their global research network to provide better customer services.
Phase Insights
Phase III segment led the market and accounted for 53.3% of the total revenue share in 2023. clinical trial statistics indicate market growth due to rising phase III trials, involving a large number of subjects. The median cost for a single-phase III trial is over USD 19.0 million. Also, phase III requires a higher number of patients and often a longer treatment period. According to a clinical trial logistics survey by Nice Insights, 35.0% of phase III clinical trials are outsourced and the number is likely to increase owing to the growing number of investigational drugs advancing to the next phase.
Study Design Insights
The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials. Interventional studies comprised over 75.0% of the total registered studies in 2022,ut of which most were for drug or biologics, followed by clinical procedure, behavioral, and device interventional studies. These studies contribute to 94.0% of the total studies that posted results, out of which drug or biologics contribute the most, followed by behavioral, devices, and Clinical procedure intervention studies.
Indication by Study Design Insights
The interventional trials market for autoimmune/inflammation accounted for the largest revenue share in 2023. This can be attributed to large number of interventional studies on autoimmune/inflammation worldwide. Numerous advantages of interventional studies, such as minimization of confounding effects, avoidance of bias in allocation to exposure groups, and efficient detection of small to moderate clinically important effects. There are over 8,900 interventional studies listed on Clinicaltrails.gov related to autoimmune/inflammation.
Indication Insights
Oncology segment accounted for the largest revenue share in 2023. As per the U.S. FDA and various other sources, more than USD 38.0 billion is currently being spent by the pharmaceutical industry on the pre-clinical and clinical development of oncology therapy products. The cardiovascular condition segment is also anticipated to witness lucrative growth over the forecast period. The growing prevalence and increased demand for cost-effective medications worldwide have led to significant investment in R&D in this segment with more than 190 drugs in the pipeline.
Sponsors Insights
Pharmaceutical & biopharmaceutical companies accounted for the largest revenue share in 2023. This can be attributed to the greater interest of the pharmaceutical industry in the research field. In addition, there has been an increase in the number of clinical trials funded by pharmaceutical & biopharmaceutical companies. The pharmaceutical industry plays a vital role in financing the research for the development of new drugs.
Regional Insights
North America accounted for 50.3% of the global market in 2023 and is expected to continue its dominance over the forecast period. This can be attributed to an increase in R&D investments and a rise in the adoption of new technologies in clinical trials in this region. For instance, the implementation of virtual services in various stages of clinical trials by market players, such as IQVIA and PRA Health Sciences, is anticipated to further propel the North American market growth.
Browse through Grand View Research's Petrochemicals Industry Research Reports.
• The global ethylene oxide market size was valued at USD 36.10 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2030.
• The global vacuum grease market size was valued at USD 139.1 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2024 to 2030.
Key Companies & Market Share Insights
The global clinical trials market is highly competitive. Some of the players operating in the market include IQVIA, PAREXEL International Corporation, Pharmaceutical Product Development, LLC, and Charles River Laboratory. The major factor influencing the competitive nature is the quick adoption of advanced technology for improved healthcare. In addition, to retain their market share and expand their product portfolio, major players are often involved in mergers and acquisitions as well as initiating new product launches.
Key Clinical Trials Companies:
• Pharmaceutical Product Development, INC. (Thermo Fisher Scientific, Inc.)
• ICON plc
• Charles River Laboratories International, Inc.
• IQVIA
• SYNEOS HEALTH
• SGS SA
• PAREXEL International Corporation
• Wuxi AppTec, Inc
• Chiltern International Ltd (Laboratory Corporation of America)
• Eli Lilly and Company
• Novo Nordisk A/S
• Pfizer
• Clinipace (Caidya)
Metalworking Fluids Market Segmentation
Grand View Research has segmented the global metalworking fluid market report based on product, application, end-use, industrial end-use, and region:
Metalworking Fluids Product Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2030)
• Mineral
• Synthetic
• Bio-Based
Metalworking Fluids Application Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2030)
• Neat Cutting Oil
• Water Cutting Oil
• Corrosion Preventive Oil
• Others
Metalworking Fluids End-use Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2030)
• Metal Fabrication
• Transportation Equipment
• Machinery
• Others
Metalworking Fluids Industrial End-use Outlook (Volume, Kilotons; Revenue, USD Million, 2018 – 2030)
• Construction
• Electric & Power
• Agriculture
• Automobile
• Aerospace
• Rail
• Marine
• Telecommunications
• Health Care
Metalworking Fluids Regional Outlook (Volume, Kilotons; Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o U.K.
o Russia
o Italy
o Spain
o Turkey
o Switzerland
o Denmark
o Norway
o Belgium
o Poland
o Czech Republic
o Sweden
o Finland
• Asia Pacific
o China
o Japan
o South Korea
o India
o Singapore
o Malayasia
o Thailand
o Australia
o New Zealand
• Central & South America
o Brazil
• Middle East & Africa
Order a free sample PDF of the Metalworking Fluids Market Intelligence Study, published by Grand View Research.
Recent Developments
• In August 2023, Parexel & Partex entered a strategic partnership aimed at utilizing Artificial Intelligence (AI)-driven solutions to expedite the process of drug discovery and development for biopharmaceutical clients globally. The collaboration aimed to reduce risks associated with the assets in their respective portfolios.
• In August 2023, Novo Nordisk announced to acquire Inversago Pharma. This acquisition was part of Novo Nordisk's strategic efforts to develop new therapies targeting individuals with obesity, diabetes, and other significant metabolic diseases
• In April 2022, Charles River Laboratories International, Inc. disclosed its acquisition of Explora BioLabs Holdings, Inc., a leading provider of contract vivarium research services.